	US 12,006,356 B2
	Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
Susan Byrne, Seattle, WA (US); Richard Sullivan, Seattle, WA (US); and Francois Vigneault, Seattle, WA (US)
Assigned to Juno Therapeutics, Inc., Seattle, WA (US)
Appl. No. 16/771,954
Filed by Juno Therapeutics, Inc., Seattle, WA (US)
PCT Filed Dec. 14, 2018, PCT No. PCT/US2018/065866 § 371(c)(1), (2) Date Jun. 11, 2020, PCT Pub. No. WO2019/118937, PCT Pub. Date Jun. 20, 2019.
Claims priority of provisional application 62/599,682, filed on Dec. 15, 2017.
Prior Publication US 2021/0070845 A1, Mar. 11, 2021
Int. Cl. C07K 16/18 (2006.01); A61K 47/68 (2017.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 19/00 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 16/18 (2013.01) [A61K 47/6803 (2017.08); A61K 47/6843 (2017.08); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2806 (2013.01); C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C12N 5/0636 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)]

28 Claims

1. An antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment binds to a peptide sequence comprising the sequence TSVEDYKA (SEQ ID NO:70), SSVEAFKR (SEQ ID NO:71) or DSVEAIKA (SEQ ID NO:72), and wherein the antibody or antigen-binding fragment comprises

a heavy chain variable (V_H) region comprising the amino acid sequence set forth in SEQ ID NO:1; and

a light chain variable (V_L) region comprising the amino acid sequence set forth in SEQ ID NO:2.